Skip to Content


In the US, Raltegravir (raltegravir systemic) is a member of the drug class integrase strand transfer inhibitor and is used to treat HIV Infection and Occupational Exposure.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antiviral agent

Treatment of HIV infection

HIV integrase inhibitor

Chemical Names

N-[(4-Fluorophenyl)metyl]-5-hydroxy-1-metyl-2-[2-(5-metyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide (WHO)

4-Pyrimidinecarboxamide, N-((4-fluorophenyl)metyl)-1,6-dihydro-5-hydroxy-1-metyl-2-(1-metyl-1-(((5-metyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)etyl)-6-oxo-

5-Hydroxy-1-metyl-2-{1-metyl-1-[(5-metyl[1,3,4]oxadiazol-2-carbonyl)amino]etyl}-6-oxo-1,6-dihydropyrimidin-4-carbonsäure-4-fluorbenzylamid (IUPAC)


Foreign Names

  • Raltegravirum (Latin)
  • Raltegravir (German)
  • Raltégravir (French)
  • Raltegravir (Spanish)

Generic Names

  • Raltegravir (OS: BAN)
  • c-1605 (IS)
  • MK-0518 (IS)
  • MK-518 (IS: Merck)
  • Raltegravir Potassium (OS: USAN, BANM, JAN)
  • 4-Pyrimidinecarboxamide (IS)

Brand Names

  • Isentress
    Merck Sharp & Dohme, Bosnia & Herzegowina; Merck Sharp & Dohme, Colombia; Merck Sharp & Dohme, Greece; Merck Sharp & Dohme, Hong Kong; Merck Sharp & Dohme, Mexico; Merck Sharp & Dohme, Malaysia; Merck Sharp & Dohme, Slovakia; Merck Sharp & Dohme, Taiwan; MSD, Costa Rica; MSD, Denmark; MSD, Dominican Republic; MSD, Guatemala; MSD, Honduras; MSD, Nicaragua; MSD, Netherlands; MSD, Panama; MSD, El Salvador; MSD, Thailand; MSD, South Africa; MSD Belgium, Belgium
  • Dutrebis (Raltegravir and Lamivudine)
    Merck Sharp & Dohme, United States
  • Isentress
    Merck, Canada; Merck Sharp & Dohme, Austria; Merck Sharp & Dohme, Australia; Merck Sharp & Dohme, Chile; Merck Sharp & Dohme, Czech Republic; Merck Sharp & Dohme, Spain; Merck Sharp & Dohme, United Kingdom; Merck Sharp & Dohme, Georgia; Merck Sharp & Dohme, Croatia (Hrvatska); Merck Sharp & Dohme, Israel; Merck Sharp & Dohme, Iceland; Merck Sharp & Dohme, Lithuania; Merck Sharp & Dohme, New Zealand; Merck Sharp & Dohme, Poland; Merck Sharp & Dohme, Portugal; Merck Sharp & Dohme, Romania; Merck Sharp & Dohme, Serbia; Merck Sharp & Dohme, United States; MSD, Argentina; MSD, Switzerland; MSD, China; MSD, Finland; MSD, Ireland; MSD, Japan; MSD, Norway; MSD, Sweden; MSD France, France; MSD Italia, Italy; MSD Pharma, Hungary
    Merck Sharp & Dohme, Latvia; MSD Merck Sharp & Dohme, Germany
  • Isentress Suspension
    Merck Sharp & Dohme, United Kingdom


BANBritish Approved Name
BANMBritish Approved Name (Modified)
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.